Predict your next investment

HEALTHCARE | Drug Development
aerami.com

See what CB Insights has to offer

Executives

4

Board of Directors

3

Aerami Therapeutics Board of Directors

3 Board of directors

Aerami Therapeutics has 3 board of directors, including Anne Whitaker.

Name

Firm

Work History

Other Seats

Anne Whitaker

Anne is a seasoned healthcare executive with more than 28 years of experience across multiple companies and geographies. She has a proven track record of building and leading high-performance teams to successfully commercialize pharmaceuticals, consumer products and medical devices. Anne has been recognized in the pharmaceutical industry by Fierce Pharma as one of the top 25 Most Influential People in BioPharma in 2012 and 2013, and in 2014 as one of the top 25 Most Influential Women in BioPharma. She was recently recognized by PharmaVoice as one of the Top 100 most Inspiring Leaders in Healthcare and by Women, Inc. as one of the most Influential Corporate Directors in 2019. She is a member of Women Corporate Directors, Healthcare Businesswomen’s Association, International Women’s Forum and OnBoardNC. Anne is the current Chairman of Aerami Therapeutics, She serves as an independent director on the board of Cree, Mallinckrodt, and UDG Healthcare. She also serves on the Board of Trustees for the Univ. of North Alabama, her alma mater. She is an active industry advisor to private equity and venture capital funds in the US and Europe. Anne served as the President of the North America Region Head where she led team to deliver ~$10B in net sales equaling > 30% of the net sales. Anne served as the CEO and President of Synta Pharmaceuticals, in 2014 and 2015. She joined Bausch Health as an Ex. VP and Company Group Chairman for the Branded Pharmaceuticals segment in mid-2015. Later she served as the CEO and President of Novoclem Therapeutics, Inc. Anne holds a Bachelor of Science degree in chemistry from the University of North Alabama

Aerami Therapeutics

Donald Huffman

Board Member -- senior financial/corporate development executive -- life science, high technology and international manufacturing industries. Experience in Fortune 200, mid-size, start-up / development stage firms -- public and private -- and venture capital. • Established productive relationships with the investment community and arranged corporate collaborations. • Raised over $1 billion in equity and debt financing including public offerings, private placements, venture debt, bank revolving credits, sale/leasebacks, tax-exempt bonds, leases and commercial paper. • Successfully arranged financing in IPO, high growth and challenging situations. • Experienced in strategic planning, corporate/business development, managing growth and day-to-day operations. • Structured and negotiated transactions, including mergers, acquisitions and spin-outs. • Assisted in raising a $420 million biomedical venture capital fund.

Aerami Therapeutics

Samantha Miller

Aerami Therapeutics

Name

Anne Whitaker

Donald Huffman

Samantha Miller

Firm

Work History

Anne is a seasoned healthcare executive with more than 28 years of experience across multiple companies and geographies. She has a proven track record of building and leading high-performance teams to successfully commercialize pharmaceuticals, consumer products and medical devices. Anne has been recognized in the pharmaceutical industry by Fierce Pharma as one of the top 25 Most Influential People in BioPharma in 2012 and 2013, and in 2014 as one of the top 25 Most Influential Women in BioPharma. She was recently recognized by PharmaVoice as one of the Top 100 most Inspiring Leaders in Healthcare and by Women, Inc. as one of the most Influential Corporate Directors in 2019. She is a member of Women Corporate Directors, Healthcare Businesswomen’s Association, International Women’s Forum and OnBoardNC. Anne is the current Chairman of Aerami Therapeutics, She serves as an independent director on the board of Cree, Mallinckrodt, and UDG Healthcare. She also serves on the Board of Trustees for the Univ. of North Alabama, her alma mater. She is an active industry advisor to private equity and venture capital funds in the US and Europe. Anne served as the President of the North America Region Head where she led team to deliver ~$10B in net sales equaling > 30% of the net sales. Anne served as the CEO and President of Synta Pharmaceuticals, in 2014 and 2015. She joined Bausch Health as an Ex. VP and Company Group Chairman for the Branded Pharmaceuticals segment in mid-2015. Later she served as the CEO and President of Novoclem Therapeutics, Inc. Anne holds a Bachelor of Science degree in chemistry from the University of North Alabama

Board Member -- senior financial/corporate development executive -- life science, high technology and international manufacturing industries. Experience in Fortune 200, mid-size, start-up / development stage firms -- public and private -- and venture capital. • Established productive relationships with the investment community and arranged corporate collaborations. • Raised over $1 billion in equity and debt financing including public offerings, private placements, venture debt, bank revolving credits, sale/leasebacks, tax-exempt bonds, leases and commercial paper. • Successfully arranged financing in IPO, high growth and challenging situations. • Experienced in strategic planning, corporate/business development, managing growth and day-to-day operations. • Structured and negotiated transactions, including mergers, acquisitions and spin-outs. • Assisted in raising a $420 million biomedical venture capital fund.

Other Seats

Aerami Therapeutics

Aerami Therapeutics

Aerami Therapeutics

Aerami Therapeutics Management Team

4 Team Members

Aerami Therapeutics has 4 executives. Aerami Therapeutics's current Chief Executive Officer is Steve Thornton.

Name

Work History

Title

Status

Steve Thornton

Chief Executive Officer

Current

Timm Crowder

President, Chief Operating Officer

Current

Anne Whitaker

Chief Executive Officer

Former

Tyler Martin

President

Former

Name

Steve Thornton

Timm Crowder

Anne Whitaker

Tyler Martin

Work History

Title

Chief Executive Officer

President, Chief Operating Officer

Chief Executive Officer

President

Status

Current

Current

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.